Decoy Therapeutics pursues FDA Animal Rule program and non-dilutive grants

Decoy Therapeutics says it plans a pan-filovirus program under the FDA Animal Rule, is pursuing non-dilutive grants and partnerships, and notes potential Priority Review Voucher monetization if approved.